A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.
- DOI
- 10.1158/2767-9764.crc-23-0361
- Published
- 2024 Jan 4
- Container
- Cancer research communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/2767-9764.crc-23-0361,
title = {A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.},
author = {Tabernero J and Yoshino T and Stintzing S and de Gramont A and Gibbs P and Jonker DJ and Nygren P and Papadimitriou C and Prager GW and Tell R and Lenz HJ},
year = {2024},
journal = {Cancer research communications},
doi = {10.1158/2767-9764.crc-23-0361},
url = {https://doi.org/10.1158/2767-9764.crc-23-0361}
}RIS
TY - JOUR TI - A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. AU - Tabernero J AU - Yoshino T AU - Stintzing S AU - de Gramont A AU - Gibbs P AU - Jonker DJ AU - Nygren P AU - Papadimitriou C AU - Prager GW AU - Tell R AU - Lenz HJ PY - 2024 JO - Cancer research communications DO - 10.1158/2767-9764.crc-23-0361 UR - https://doi.org/10.1158/2767-9764.crc-23-0361 ER -
APA
J, T., T, Y., S, S., A, D. G., P, G., DJ, J., P, N., C, P., GW, P., R, T., & HJ, L. (2024). A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.. Cancer research communications. https://doi.org/10.1158/2767-9764.crc-23-0361
Source records
- pubmed · retrieved 2026-09-26T22:13:41.882Z